Salute e Benessere

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4…

GZR18 Injection: a Phase 2 Study evaluate the Efficacy and Safety of GZR18 Injective vs. Semaglutide (Ozempic®) in Chinese Patients with Type 2 DiabetesThe Phase 2b clinical trial (CTR20232069) is a multicenter, randomized, open-label study comparing the efficacy and safety of GZR18 injection versus semaglutide (Ozempic®) in Chinese adult T2D patients with poor glycemic control on lifestyle interventions and/or unregulated use of anti-diabetic drugs, and on oral anti-diabetic treatment for at…
PR Newswire
15/10/2024

Epitomee Medical to Present the Epitomee Breakthrough Oral Delivery Platform at…

Epitomee's presentation will cover the following topics: Epitomee's presentation will cover the following topics: The PODD Conference, in its 14th year, brings together over 800+ delegates from pharma, biotech, drug delivery, investors and academia. The event fosters collaboration across industries, to develop more effective therapies, improve the patient experience and extend the lifecycle of medicines. PODD features innovative technologies to enhance the delivery of various drug types,...
PR Newswire
15/10/2024

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of…

uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162 for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in superoxide dismutase 1 (SOD1), a rare, inherited and progressive motor neuron disease. EPISOD1 is a Phase I/II multi-center, open-label trial being conducted in the United States with...
Nasdaq GlobeNewswire
15/10/2024

Lutris Pharma Completes Enrollment in Phase 2 Trial of LUT014 for the Treatment…

The phase 2, randomized, double-blind, placebo-controlled trial has enrolled a total of 117 subjects at 20 international sites, including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and Dana Farber Cancer Institute. The trial is evaluating the efficacy and safety of two strengths of LUT014 gel, 0.03% or 0.10%, applied once daily for 4 weeks, compared to placebo (with a randomization of 1:1:1), in patients with mCRC who develop Grade 2 or non-infected Grade 3 EGFR…
PR Newswire
15/10/2024

New research reveals hidden cybercrime mental health crisis

A survey of 1,002 Britons who have been a victim of cybercrime in the past year, commissioned by Akamai, reveals most are ashamed of their experience, feel they've done something wrong, and believe there's an unfair stigma placed on them. A survey of 1,002 Britons who have been a victim of cybercrime in the past year, commissioned by Akamai, reveals most are ashamed of their experience, feel they've done something wrong, and believe there's an unfair stigma placed on them. Cybercrime causes...
PR Newswire
15/10/2024

Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in…

®, Hong Kong trade name: LOQTORZI ® ) has been approved for marketing in India and China's Hong Kong Special Administrative Region (“SAR”), for treatment of recurrent or metastatic nasopharyngeal carcinoma (“NPC”). The approved indications are: 1) toripalimab in combination with cisplatin and gemcitabine, for first line treatment of adults with metastatic or with recurrent, locally advanced NPC; 2) toripalimab as a single agent, for the treatment of adults with recurrent unresectable or...
Nasdaq GlobeNewswire
15/10/2024

WARBURG PINCUS STRENGTHENS ITS EUROPEAN BUSINESS AND GLOBAL HEALTHCARE GROUP…

The senior adviser appointments follow the recent announcement of Enovo Life Sciences, a new life sciences platform institutionally capitalized by funds advised by Warburg Pincus and led by life sciences industry veterans, Mario Philips and Roel Gordijn. These announcements demonstrate the continued momentum in Warburg Pincus's European business. Jake Strauss, a Managing Director in the global healthcare group, was recently announced as head of the firm's European healthcare efforts and Tobias…
PR Newswire
15/10/2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Company Announcement Net sales of DARZALEX ®in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; October 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX ®(daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEXFASPRO® ...
Nasdaq GlobeNewswire
15/10/2024

Alimentiv and Satisfai Health Extend Partnership to Accelerate Development of…

"AI-powered standardization of disease scoring provides unprecedented insights, transforming data analysis and ultimately leading to better treatment outcomes for patients in clinical trials. As the leader in the field, Alimentiv will continue to lead this space and invest in innovative imaging solutions to provide more accurate analyses, highly competitive trial costs, and support sponsors with faster timelines," said Pierre Gaudreault, CEO, Alimentiv. "AI-powered standardization…
PR Newswire
15/10/2024

Boehringer Ingelheim and WHO Foundation join forces to promote equitable access…

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare services for all, with a special focus on vulnerable populations in the Americas who are at greater risk of suicide.Through this partnership with the WHO Foundation, Boehringer Ingelheim will provide financial support to WHO's Fourteenth General Program of Work, spanning from 2025 to 2028,...
Nasdaq GlobeNewswire
15/10/2024

AuriGen Medical Pioneers Next-Generation Atrial Fibrillation Technology with…

Atrial fibrillation ("AF") affects over 60 million people worldwide and significantly increases stroke risk, with over 90% of stroke-causing clots originating in the left atrial appendage ("LAA"). This makes LAA closure vital for patients who cannot tolerate long-term anticoagulation therapy. The Zenith device simplifies LAA closure, crucial for reducing stroke risk in AF patients. Atrial fibrillation ("AF") affects over 60 million people worldwide and significantly…
PR Newswire
15/10/2024

Commit Biologics appoints Mikkel Wandahl Pedersen as Chief Scientific Officer

Prior to Nykode, Dr Pedersen served as CSO of Symphogen (Ballerup, Denmark), where he held broad R&D responsibilities for the antibody discovery platform, lead discovery, pre-clinical as well as translational pharmacology, and advanced a number of products through IND studies and into the clinic. Following the acquisition of Symphogen by Servier, he played a critical role in the integration of the R&D team. Prior to Nykode, Dr Pedersen served as CSO of Symphogen (Ballerup,Denmark )…
PR Newswire
15/10/2024

MaineGeneral Health in the US selects Sectra's enterprise imaging SaaS to help…

Based in Augusta, MaineGeneral Health serves central Maine through a network of hospitals and outpatient facilities. In September 2024, they signed a 5-year agreement for Sectra One Cloud, and will utilize the modules for radiology and breast imaging, as well as the vendor-neutral archive (VNA). MaineGeneral Health performs approximately 200,000 exams annually. Based inAugusta, MaineGeneral Health serves centralMainethrough a network of hospitals and outpatient facilities. InSeptember...
PR Newswire
15/10/2024

Orion publishes Interim Report for January–September 2024 and holds a webcast on…

ORION CORPORATIONPRESS RELEASE15 OCTOBER 2024 at 9.00 EEST Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024 Orion will publish Interim Report for January–September 2024 on Tuesday, 29 October 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company's website at www.orion.fi/en/investors after publishing. Webcast and conference call A webcast and a conference call for...
Nasdaq GlobeNewswire
15/10/2024

Avacta Group strengthens executive team with appointment of Michelle Morrow…

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific OfficerLondon, Oct. 15, 2024 – Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announced the appointment of seasoned scientific leader Michelle Morrow, PhD as Chief Scientific Officer with effect from November 4, 2024. Dr. Morrow brings nearly 20…
Nasdaq GlobeNewswire
15/10/2024

ONWARD® Medical Signs Agreement with CEA for Exclusive Rights to Clinatec's…

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Company secures exclusive rights to incorporate the WIMAGINE BCI into its ARC-BCI™ SystemWIMAGINE BCI has 7-year human safety dataDeal provides opportunity for ONWARD to be first-to-market with a BCI-enabled system to restore thought-driven movement after paralysisEINDHOVEN, the Netherlands, Oct.15, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N...
Nasdaq GlobeNewswire
15/10/2024

Aidoc and Integral Diagnostics (IDX) Expand AI Partnership in Australia and New…

Aidoc's AI technology has firmly positioned IDX as the market leader in AI-driven medical imaging in Australia and New Zealand, with its aiOS™ platform automatically flagging critical pathologies, including brain aneurysms, pulmonary embolisms, stroke, and brain bleeds. Aidoc's AI technology has firmly positioned IDX as the market leader in AI-driven medical imaging inAustraliaandNew Zealand, with its aiOS™ platform automatically flagging critical pathologies, including brain aneurysms,...
PR Newswire
15/10/2024

CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to…

Key Takeaways from the CDK4/6 Inhibitors Market Report Key Takeaways from the CDK4/6 Inhibitors Market Report Discover which therapies are expected to grab the CDK4/6 inhibitors market share @ CDK4/6 Inhibitors Market Report CDK4/6 Inhibitors Market Dynamics The CDK4/6 inhibitors market has experienced significant growth in recent years, primarily driven by the increasing incidence/prevalence of cancer, particularly breast cancer. CDK4/6 inhibitors, such aspalbociclib,...
PR Newswire
14/10/2024

Information regarding the total number of voting rights and total number of…

Information regarding the total number of voting rights and totalnumberofsharesoftheCompany asofSeptember30,2024 (Article 223-16 of the General Regulations of theAutoritédesMarchésFinanciers )Market : NYSE Euronext Paris ISIN Code: FR 0010417345 DateTotalnumberofsharesTotalnumberofvotingrights 09/30/2024 96,501,526 Total gross of voting rights: 96,501,526Total net* of voting rights:...
Nasdaq GlobeNewswire
14/10/2024

Inventiva announces the availability of a prospectus in connection with its…

Daix (France), Long Island City (New York, United States), October 14, 2024– Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”) and other diseases with significant unmet medical needs, today announces that theAutorité des marchés financiers(the “ AMF ”) has approved a...
Nasdaq GlobeNewswire
14/10/2024

Ipsen receives its second Shingo Prize for operational excellence

Ipsen is the first pharma company in the world to receive Shingo Prizes for two sites producing treatments for patientsIpsen's first Shingo Prize was received by its production site in Signes, France in 2020, followed by the site in Dublin, Ireland todayThe Shingo Prize represents the highest standard of operational excellence in the worldPARIS, FRANCE, 14 October 2024 -Ipsen (Euronext: IPN; ADR: IPSEY) announced today that its Dublin, Ireland production site has...
Nasdaq GlobeNewswire
14/10/2024

Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in…

Scientists from illuma and Nestlé were among the first to realize the significance of HMOs in human milk more than 30 years ago. Their pioneering research led to over 75 published papers; over 100 patents relating to HMOs. The brand has carried out more than 55 HMO-related studies, including more than 30 clinical trials. Children worldwide can now benefit from multifunctional HMOs thanks to the application of these study findings, which have led to the provision of a wide range of HMO-containing…
PR Newswire
14/10/2024

Halal Empty Capsules Market Hit USD 1.55 Billion by 2029 with 5.4% CAGR |…

Browse in-depth TOC on "Halal Empty Capsules Market" Browse in-depth TOC on "Halal Empty Capsules Market" 123 - Tables40 - Figures154 - Pages The type of segment is segmented into gelatin and non-gelatin. The gelatin halal empty capsules segment dominated type segments owing to various factors such as availability of bovine gelatin, particularly from halal-certified suppliers, and their widespread use, affordability, and ease of production. The non-gelatin segment is...
PR Newswire
14/10/2024

"Maxima Grupė" Supervisory Board Dissolved

On October 14, 2024, UAB "Vilniaus Prekyba," the sole shareholder of MAXIMA GRUPĖ, UAB, decided to dissolve the company's Supervisory Board and approve a new version of the company's articles of association accordingly. The Supervisory Board, which consisted of three members from affiliated companies within the "Vilniaus Prekyba" group, functioned as a non-mandatory corporate governance body. The decision to discontinue the Supervisory Board was made to simplify the company's…
Nasdaq GlobeNewswire
14/10/2024
Altri  Comunicati